
SI-BONE Inc (SIBN) Stock Forecast & Price Target
SI-BONE Inc (SIBN) Analyst Ratings
Bulls say
SI-BONE Inc. has demonstrated a positive financial trajectory with a gross margin increase of approximately 80 basis points year-over-year, reaching 79.8% in the second quarter of 2025. Revenue for the same quarter rose about 23% year-over-year to $46.4 million, highlighting a strong demand for its innovative medical devices. Additionally, the company expanded its surgeon base by approximately 25% year-over-year, contributing to a production increase of $2.1 million, also up about 23% year-over-year, indicating robust market traction for its products.
Bears say
SI-BONE Inc faces significant challenges in the global spine market, which has been experiencing pricing and procedure headwinds that have resulted in low-single-digit growth in recent years. These persistent headwinds threaten SI-BONE's market share in the sacroiliac joint fusion market, particularly if payors opt to reimburse for competing products, potentially leading to a decline in the company's top-line revenue. Furthermore, industry-wide expectations suggest that these difficulties are likely to persist, contributing to a depressed outlook for overall market growth.
This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.
SI-BONE Inc (SIBN) Analyst Forecast & Price Prediction
Start investing in SI-BONE Inc (SIBN)
Order type
Buy in
Order amount
Est. shares
0 shares